FDA Announces Scientific and Regulatory Clarity Measures to Promote the Development of Complex Generic Drugs
High Entry Barriers for Complex Generics and the Need for Market Competition
Complex Generic Drugs are significantly more difficult to develop than conventional generics due to their complex active ingredients, unique formulations, or integration with specific drug delivery devices. Until now, the lack of clear approval criteria has led to uncertainty for pharmaceutical companies during the application process, discouraging investment. This has perpetuated the high price barriers of original proprietary drugs, increasing the financial burden on patients. The U.S. Food and Drug Administration (FDA) has now detailed a plan to overcome these structural limitations, aiming to stimulate competition in the complex generic market and significantly improve patient access to healthcare.
Promotion Plan for Complex Generics with Scientific and Regulatory Clarity
The core of this plan is to provide comprehensive scientific and regulatory clarity (Scientific and Regulatory Clarity) throughout the entire lifecycle—from pre-submission stages to final approval. To achieve this, the FDA is proactively publishing and expanding the scope of Product-Specific Guidances (PSG), which include detailed recommendations for specific drugs. Additionally, the Pre-Abbreviated New Drug Application (Pre-ANDA) Program, an early communication channel between researchers and regulatory reviewers, is being used to reduce trial-and-error before preliminary submissions. This helps pharmaceutical companies minimize the number of Complete Response Letters (CRLs), which are requests for additional information, thereby significantly reducing the time and cost required to obtain approval.
Academic Collaboration and Regulatory Science Research to Overcome Technical Bottlenecks
Beyond establishing its own guidelines, the FDA is actively leveraging the Center for Research on Complex Generics (CRCG) to drive technical collaboration with academia and the pharmaceutical industry. Through this research center, jointly operated by the University of Maryland and the University of Michigan, advanced analytical methods are being developed to support the demonstration of equivalence for high-complexity drug delivery systems such as liposomes, micelles, and inhalants. By proactively setting scientific standards in regulatory guidelines, the agency is effectively sharing the risk of early-stage analytical research, which individual companies may find difficult to bear. This investment in regulatory science is acting as a catalyst for mid-sized and large pharmaceutical companies with strong technical capabilities to aggressively pursue high-value complex generic pipelines.
Global Pharmaceutical Companies Forming Alliances to Capture High-Value Generic Markets
This regulatory environment shift is expected to accelerate the growth of the global complex generic market and reshape the global generic ecosystem. The global complex generic market, valued at approximately $90.68 billion in 2025, is projected to grow at an annual rate of 8.1% and reach $213.6 billion by 2036. In response, global generic leaders such as Viatris (VTRS), Teva (TEVA), and Sandoz (SDZ) are rapidly increasing R&D investments in biosimilars and complex formulations as patent expirations approach, using regulatory clarity as a foundation. As a result, partnerships between CMO/CDMO companies in the Asia-Pacific region with advanced formulation technologies and large pharmaceutical companies with global distribution networks are expected to become even more robust.
The FDA's initiative to promote complex generics will act as a catalyst for reducing entry barriers into a market valued at $90.68 billion in 2025, thereby stimulating price competition. In the short term, the expansion of product-specific guidelines (PSG) will significantly reduce errors and clinical cost burdens for global generic companies such as Teva (TEVA) and Sandoz (SDZ) during the ANDA submission phase. In the medium to long term, the monopolistic dominance of blockbuster pipelines by multinational original drug manufacturers is expected to rapidly erode, accelerating market realignment for follow-on biosimilars and improved new drugs. Particularly for researchers and investors aiming to expand global CDMO operations with high-complexity formulation technologies, the initiative will serve as a key indicator for improving approval success rates under clear regulatory guidelines.